Loading patent…
AssigneeMedizinische Hochschule Hannover
InventorsAxel Schambach, Katharina Zimmermann, Hinrich Abken, Johannes Kühle
Estimating the term…
Immune cells containing a nucleic acid construct, also referred to as a vector or viral vector, for use in immune therapy, e.g. for use in the treatment of cancer, or for use in the treatment of autoimmune disease, or for use in the treatment of GvH or HvG. The nucleic acid construct comprises a second expression cassette for constitutive expression of a CAR or a TCR, the binding of which to its target antigen results in signalling and induces the expression of an effector molecule from a first expression cassette, which is contained on the same nucleic acid construct, and which first expression cassette encodes the effector molecule under the control of a promoter inducible by signalling of the CAR or TCR.
A nucleic acid construct for expression of an effector molecule in response to the presence of a target antigen of a chimeric antigen receptor (CAR) or a T-cell receptor (TCR), wherein the nucleic acid construct in one strand comprises a first expression cassette, comprising a first promoter which is inducible by binding of a CAR or TCR to its target antigen to control expression of a coding sequence for the effector molecule, and a second expression cassette encoding the CAR or TCR under the control of a constitutive second promoter, wherein the nucleic acid construct is part of a lentiviral vector, of an alpha (α)-retroviral vector or of a gamma (γ)-retroviral vector, and wherein the first expression cassette is arranged in 5′ of the second expression cassette, and wherein between the first expression cassette and the second expression cassette there is no poly-adenylation signal and wherein a poly-adenylation signal is contained in an LTR that is arranged in the 3′ end of the second expression cassette.
Dependencies are inferred from the claim text.